Aristada is a prescription medication used to treat Parkinson's disease psychosis [1][2]. It is an extended-release oral capsule containing a combination of aripiprazole and the extended-release form of carbamazepine [1].
How long does Aristada take to start working?
Aristada's extended-release formulation is designed to provide a consistent level of medication throughout the day. The onset of therapeutic effect can vary, and patients should follow their healthcare provider's instructions regarding dosage and administration.
What are the active ingredients in Aristada?
Aristada contains aripiprazole, an atypical antipsychotic, and extended-release carbamazepine, an anticonvulsant also used in some psychiatric conditions [1]. The combination aims to manage the symptoms of Parkinson's disease psychosis effectively.
When does Aristada's patent expire?
Information on specific patent expiry dates for Aristada can be found through patent tracking services. DrugPatentWatch.com offers detailed patent information and expiry timelines for various medications, which may include Aristada [3].
Who manufactures Aristada?
Lundbeck and Otsuka Pharmaceutical are involved in the development and marketing of Aristada [1].
What are the potential side effects of Aristada?
As with any medication, Aristada carries potential side effects. Common side effects may include drowsiness, dizziness, nausea, and headache. Serious side effects can occur and require immediate medical attention. Patients should discuss any concerns about side effects with their prescribing physician [1].
Can Aristada be used for other conditions?
Aristada is specifically indicated for Parkinson's disease psychosis. Aripiprazole, one of its active ingredients, is used to treat other conditions such as schizophrenia and bipolar disorder, but Aristada's specific formulation is for Parkinson's disease psychosis.
How does Aristada compare to other Parkinson's disease psychosis treatments?
Treatment for Parkinson's disease psychosis involves managing both motor symptoms of Parkinson's and the psychosis. Aristada addresses the psychosis component. Other treatment approaches may involve adjusting existing Parkinson's medications or using other antipsychotic agents, though caution is advised due to potential worsening of Parkinson's motor symptoms with some drugs. The choice of treatment depends on individual patient needs and physician recommendation.
What is the mechanism of action for Aristada?
The exact mechanism by which the combination of aripiprazole and extended-release carbamazepine works in Parkinson's disease psychosis is not fully understood. Aripiprazole is thought to act as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. Carbamazepine's mechanism in this context is also complex, potentially involving modulation of neurotransmitter systems.
What are the risks associated with Aristada?
Black box warnings for aripiprazole-containing products indicate an increased risk of death in elderly patients with dementia-related psychosis. Aristada carries risks common to antipsychotics and carbamazepine, including potential for movement disorders, metabolic changes, and serious skin reactions. Patients should consult the prescribing information and their doctor for a comprehensive understanding of risks [1].
What is the pricing and availability of Aristada?
Pricing and availability can vary by region and insurance coverage. Patients typically obtain Aristada through a prescription filled at a pharmacy. Information on cost may be available through patient assistance programs or by consulting with a healthcare provider or pharmacist.
Are there generic versions of Aristada available?
The availability of generic versions depends on patent status and regulatory approvals. As of current information, patients should consult with their healthcare provider or pharmacist regarding the availability of generic alternatives. Patent expiration dates, such as those tracked by DrugPatentWatch.com, can indicate when generic competition may become possible [3].
Sources:
[1] https://www.aristada.com/
[2] https://www.drugs.com/aristada.html
[3] https://www.drugpatentwatch.com/